Universitätsklinikum Halle
Welcome,         Profile    Billing    Logout  
 10 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Treede, Hendrik
BIOVALVE, NCT02249000: - I / II Clincial Investigation

Completed
N/A
68
Europe
BIOVALVE prosthesis
Biotronik AG, Medstar Health Research Institute
Heart Valve Diseases, Aortic Valve Stenosis
03/18
05/23
NCT02732691: JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study

Active, not recruiting
N/A
68
Europe, US, RoW
JenaValve Pericardial TAVR System
JenaValve Technology, Inc.
Aortic Valve Stenosis, Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Ventricular Outflow Obstruction
05/19
04/24
TAVIS, NCT05536310: Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease

Not yet recruiting
N/A
600
Europe
Transcatheter Aortic Valve Implantation (TAVI)
JenaValve Technology, Inc.
Aortic Valve Stenosis, Aortic Valve Regurgitation, Aortic Valve Stenosis With Insufficiency, Constriction, Pathologic, Aortic Valve Disease, Heart Valve Diseases, Cardiovascular Diseases in Old Age, Ventricular Outflow Obstruction, Aortic Stenosis, Severe
10/23
10/27
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
ARTIST, NCT06608823: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

Not yet recruiting
N/A
1016
NA
Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System, SAVR
JenaValve Technology, Inc.
Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
02/26
02/36
NCT05149755: Evolut™ EXPAND TAVR II Pivotal Trial

Recruiting
N/A
650
Europe, Canada, Japan, US, RoW
Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)
Medtronic Cardiovascular
Moderate Aortic Valve Stenosis
02/26
12/34
NCT04198870: MitraClip REPAIR MR Study

Recruiting
N/A
500
Europe, Canada, US
MitraClip™ device implantation, Mitral Valve Repair Surgery
Abbott Medical Devices
Mitral Valve Regurgitation
04/26
04/34
APOLLO-EU, NCT05496998: Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - Trial

Recruiting
N/A
400
Europe
Medtronic Intrepid™ TMVR TF System
Medtronic Cardiovascular
Mitral Regurgitation
08/29
12/38
Ronellenfitsch, Ulrich
TATRA, NCT06414031: Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery

Recruiting
3
850
Europe
Tranexamic Acid, Tranexamsäure Carinopharm 100mg/ml, Placebo, Isotone Kochsalz-Lösung 0,9% Infusionslösung
Ulrich Ronellenfitsch, MD, German Federal Ministry of Education and Research, Coordinating Centre for Clinical Trials Halle
Surgical Blood Loss, Transfusion-dependent Anemia, Abdomen Disease
11/25
11/25
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28
PRESTO, NCT05713838: Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Recruiting
2
32
Europe
Durvalumab, IMFINZI, FLOT, mFOLFOX-6, Radiotherapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophagus Adenocarcinoma
12/25
12/28
HOLIPANC, NCT04617457 / 2019-002734-37: Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas

Recruiting
2
150
Europe
nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), nal-irinotecan (nal-iri), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), ONIVYDE TM
University of Cologne, Servier
Pancreatic Cancer, Metastasis, Surgery, Oligometastatic Disease
12/24
09/25
PREVADER, NCT04136769: Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer

Terminated
N/A
3
Europe
Visceral Debranching, Revascularisation of visceral arteries
Ulrich Ronellenfitsch, MD
Pancreas Cancer
12/24
12/24
Walldorf, Jens
FRESCO, NCT03843385: Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis

Recruiting
3
174
Europe
encapsulated faecal microbiota filtrate, FMFT, encapsulated faecal microbiota, FMT, Placebo, Encapsulated sterile saline
Andreas Stallmach, German Federal Ministry of Education and Research
Ulcerative Colitis, Inflammatory Bowel Diseases
01/25
07/26
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27

Download Options